• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·4127.TWO
Share

Tien Liang BioTech Co., Ltd. Stocks

NT$ 79.8Last Updated 27.07.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

NT$ 111.71M

NT$ 79.8
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Tien Liang BioTech Co., Ltd., established in 1960 and headquartered in New Taipei City, Taiwan, is a pharmaceutical enterprise involved in the development, manufacturing, and global distribution of a diverse array of health and medicinal products. The company's offerings include traditional Chinese medicine (TCM) formulations, predominantly in pill form. These remedies address a broad spectrum of conditions, such as internal organ deficiencies (e.g., liver and kidney), various forms of musculoskeletal and neuropathic discomfort (including low back pain, joint pain, rheumatism, gout, and neuralgia), and common ailments like dizziness, digestive issues (constipation, hemorrhoids), respiratory symptoms (colds, bronchitis, coughs), and skin conditions (athlete's foot). Additionally, Tien Liang BioTech provides a range of Western pharmaceutical products. This segment features topical applications like ointments, pain relief gels, soreness sprays, and transdermal pain patches, alongside oral preparations such as tablets and capsules. The portfolio also includes specialized items like hair removal creams. Beyond pharmaceuticals, the company extends its reach into general consumer health and personal care. These offerings comprise products designed for body relaxation and comfort, items to alleviate post-exercise discomfort, oral hygiene products, and various soaps.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.07.2026 16:15

Cathie Wood's fund, which invests in the genomic revolution, has purchased shares in Scribe, a newcomer to the stock market

27.07.2026 15:45

Kazakhstan's Main Oil Export Terminal to Resume Shipments — Bloomberg

27.07.2026 15:07

Shein posted a loss ahead of its Hong Kong IPO. Revenue growth has slowed.

27.07.2026 14:48

Morning in New York: A Breather Before Key Events

27.07.2026 13:34

CXMT shares soared 466% on the first day after its IPO. An analyst expects the price to double again.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026